Osivax
Lyon
About Osivax
Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $89.3M
- Funding stage: Early Stage Venture
- Last round: Grant (Aug 2025)
- Website: osivax.com
- Phone: +33 4 37 65 55 03
Industries & Categories
Biotechnology, Clinical Trials, Health Care
Social Profiles
Canonical: https://fsome.com/organization/osivax-60536 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.